{"product_id":"hikma-pestle-analysis","title":"Hikma PESTLE Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSkip the Research. Get the Strategy.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eGain strategic clarity with our PESTLE Analysis of Hikma—revealing how political shifts, regulatory pressures, economic trends, and technological advances shape its prospects. Ideal for investors, advisors, and strategists, this concise briefing highlights key external risks and opportunities. Purchase the full, editable report to access in-depth insights and actionable recommendations you can use immediately.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eolitical factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeopolitical stability in the MENA region\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe MENA region accounts for roughly 30% of Hikma Pharmaceuticals revenues and houses key plants in Jordan and Egypt, so geopolitical instability poses material supply-chain risk; unrest in 2023–2024 led to intermittent distribution delays impacting regional sales. Hikma offsets this via government partnerships and diversified manufacturing across six countries, keeping local production levels high and enabling continued operations through 2025 with minimal revenue interruption.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUnited States healthcare policy and drug pricing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAs a major US generics and injectables player, Hikma faces headwinds from federal drug-pricing reforms—recent proposals and the Inflation Reduction Act provisions have driven downward pricing pressure, contributing to industry margin compression (US generics margins fell ~200–300 basis points industry-wide in 2023–24).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational trade agreements and tariffs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGlobal trade dynamics and tariffs on APIs or finished goods materially affect Hikma’s operations—tariff spikes between 2023–2025 raised import costs by an estimated 2–4% for industry peers, pressuring margins in generic portfolios. Changes in US–EU–emerging market relations can shift freight and duty expenses across Hikma’s supply chain hubs in Jordan, Portugal and the US, altering cost structure. Hikma leverages its multinational footprint and transfer-pricing strategies to optimize tax and trade positions, facilitating cross-border flows and supporting 2025 revenue of $1.9bn in generics. The company monitors rising protectionist measures—notably increased import duties in several African and Latin American markets in 2024–2025—that could raise raw material costs and affect product affordability.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment relations and public health investment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHikma’s branded-market success hinges on government healthcare spending and public health programs; in 2024, MENA public health budgets grew ~6% YoY supporting medicine procurement where Hikma often wins tenders.\u003c\/p\u003e\n\u003cp\u003eIn several MENA countries Hikma partners with state health authorities to supply essential medicines and bolster local infrastructure, generating predictable revenue and strengthening its reputation as a strategic healthcare partner.\u003c\/p\u003e\n\u003cp\u003eOngoing public investment in healthcare access—World Bank data shows healthcare spending per capita in emerging MENA rising—remains a tailwind for Hikma’s long-term growth in developing economies.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGovernment contracts = stable revenue; 2024 sales exposure to public markets significant in MENA\u003c\/li\u003e\n\u003cli\u003ePartnerships improve market access and brand trust\u003c\/li\u003e\n\u003cli\u003eRising public health budgets (≈6% YoY 2024) support future demand\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory harmonization and global standards\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRegulatory harmonization has cut duplicate filings, helping Hikma shorten average registration timelines by an estimated 20%—supporting faster launches of generics and in-licensed products across 50+ markets where it operates.\u003c\/p\u003e\n\u003cp\u003eActive participation in WHO and ICH forums lets Hikma align with global GMP and quality benchmarks, reducing compliance costs and accelerating time-to-market in both mature and emerging regions.\u003c\/p\u003e\n\u003cp\u003eLeveraging these political trends, Hikma expands geographic reach with lower administrative overhead, aiding revenue diversification (2024 revenue: $2.9bn; international mix \u0026gt;70%).\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~20% faster registrations\u003c\/li\u003e\n\u003cli\u003ePresence in 50+ markets\u003c\/li\u003e\n\u003cli\u003e2024 revenue $2.9bn; \u0026gt;70% international\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeopolitics, pricing \u0026amp; tariffs pressure margins as regulatory cuts boost $2.9B international sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGeopolitical instability in MENA (≈30% revenue) risks supply; government contracts and 6-country manufacturing limited disruptions. US drug-pricing pressures and IRA reduced generics margins ~200–300bps (2023–24). Tariff shifts raised import costs ~2–4% (2023–25); regulatory harmonization cut registration times ~20%, aiding launches and supporting 2024 revenue $2.9bn (\u0026gt;70% international).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMENA revenue share\u003c\/td\u003e\n\u003ctd\u003e≈30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 revenue\u003c\/td\u003e\n\u003ctd\u003e$2.9bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGenerics margin hit\u003c\/td\u003e\n\u003ctd\u003e≈200–300bps\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImport cost rise\u003c\/td\u003e\n\u003ctd\u003e≈2–4%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegistration time cut\u003c\/td\u003e\n\u003ctd\u003e≈20%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eExplores how external macro-environmental factors uniquely affect Hikma across six dimensions—Political, Economic, Social, Technological, Environmental, and Legal—backed by current data and trends to identify threats and opportunities for executives and investors.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise Hikma PESTLE summary that’s visually segmented by category for quick reference in meetings, easily dropped into presentations, and editable for regional or business-line notes to streamline team alignment and risk discussions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eE\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003economic factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCurrency volatility and exchange rate risks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHikma operates across MENA, Europe and the US, exposing reported 2024-25 earnings and cash flow to currency swings; FX moves cost Hikma c.5–8% of adjusted operating profit in prior years when MENA currencies devalued against USD\/GBP. \u003c\/p\u003e\n\u003cp\u003eSignificant devaluations or USD\/GBP shifts force use of forward contracts and swaps; management targets natural hedges by matching cost base to revenue currency, reducing net exposure by an estimated 40–60%. \u003c\/p\u003e\n\u003cp\u003eBy end-2025, treasury prioritises dynamic hedging and monthly FX stress tests after FX volatility spiked in 2023–24, keeping capital preservation and margin stability central to financial policy. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInflationary pressures on manufacturing costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGlobal inflation raised raw material, energy and labor costs, lifting COGS for pharma; input prices rose ~8-12% in 2023–2024 in key markets, squeezing margins for manufacturers including Hikma.\u003c\/p\u003e\n\u003cp\u003eHikma mitigates via operational excellence and scale-driven supplier negotiations, reporting ~USD 75m of procurement savings in 2024 through sourcing and efficiency initiatives.\u003c\/p\u003e\n\u003cp\u003eBranded products allow some pass-through pricing, but generics demand strict cost control to protect margins, prompting continued investment in automation across global sites.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRising demand for affordable generic alternatives\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEconomic pressures on healthcare budgets globally are accelerating shifts to generics and biosimilars; payers aim to cut drug spend—generic penetration rose to ~90% of prescriptions by volume in developed markets by 2024, boosting demand for lower-cost options.\u003c\/p\u003e\n\u003cp\u003eHikma’s broad portfolio of high-quality, lower-cost generics and injectables aligns with this trend, enabling capture of growing market share as governments and insurers prioritize cost savings without outcome trade-offs.\u003c\/p\u003e\n\u003cp\u003eBy late 2025 Hikma reported volume-driven revenue growth in key markets, reflecting the ongoing economic necessity for cost-effective medicines as a principal growth driver.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInterest rate environment and capital structure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eHigher global interest rates have raised Hikma Pharmaceuticals plc's borrowing costs, increasing the weighted average cost of debt and tightening financing for large acquisitions; as of 2024 Hikma reported net debt\/EBITDA around 0.9x, reflecting prudent leverage that supports deal-making flexibility.\u003c\/p\u003e\n\u003cp\u003eManagement emphasizes disciplined capital allocation, targeting projects with returns exceeding the higher hurdle rates and preserving investment-grade metrics to sustain access to credit markets.\u003c\/p\u003e\n\u003cp\u003eHikma's conservative balance sheet—cash of $450m and liquidity facilities maintained in 2024—buffers against credit market tightening and potential economic downturns, enabling continued selective M\u0026amp;A and capital expenditure.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNet debt\/EBITDA ~0.9x (2024)\u003c\/li\u003e\n\u003cli\u003eCash ~ $450m (2024)\u003c\/li\u003e\n\u003cli\u003eFocus on ROIC above rising hurdle rates\u003c\/li\u003e\n\u003cli\u003eConservative leverage to protect credit access\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGrowth of healthcare spending in emerging markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eEconomic development and a rising middle class in emerging markets have driven per capita healthcare spending growth—MENA healthcare expenditure rose to about USD 185 billion in 2023, with forecasted CAGR ~5–6% to 2028—positioning Hikma to capture higher demand in its strong Middle East and North Africa footprint.\u003c\/p\u003e\n\u003cp\u003eRising disposable incomes increase demand for branded generics and specialty treatments; Hikma’s branded generics accounted for a material share of 2024 revenues, enabling expansion into new therapeutic areas and geographies supported by favorable economic tailwinds.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMENA healthcare spend ~USD 185bn (2023), forecast CAGR ~5–6% to 2028\u003c\/li\u003e\n\u003cli\u003eHikma strong presence in MENA; branded generics drive revenue growth (material 2024 share)\u003c\/li\u003e\n\u003cli\u003eRising disposable income → higher demand for branded generics and specialty drugs\u003c\/li\u003e\n\u003cli\u003eEconomic tailwind supports therapeutic and geographic expansion\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHikma: FX headwinds vs. USD75m savings, strong MENA healthcare tailwinds\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHikma faces FX and inflationary pressure—FX cost ~5–8% of adjusted operating profit historically; procurement savings ~USD 75m (2024); net debt\/EBITDA ~0.9x and cash ~USD 450m (2024); MENA healthcare spend ~USD 185bn (2023) with ~5–6% CAGR to 2028, supporting branded generics growth and margin focus.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFX drag\u003c\/td\u003e\n\u003ctd\u003e5–8% op profit\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProcurement savings (2024)\u003c\/td\u003e\n\u003ctd\u003eUSD 75m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet debt\/EBITDA (2024)\u003c\/td\u003e\n\u003ctd\u003e~0.9x\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash (2024)\u003c\/td\u003e\n\u003ctd\u003eUSD 450m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMENA healthcare (2023)\u003c\/td\u003e\n\u003ctd\u003eUSD 185bn, 5–6% CAGR\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003eHikma PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact Hikma PESTLE Analysis document you’ll receive after purchase—fully formatted, professionally structured, and ready to use immediately.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56751869362553,"sku":"hikma-pestle-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/hikma-pestle-analysis.png?v=1772235572","url":"https:\/\/matrixbcg.com\/products\/hikma-pestle-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}